PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16542442-0	2006	Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy.	Docetaxel	102-111	bromodomain containing 4	Homo sapiens	36-40	
16542442-0	2006	Midline carcinoma with t(15;19) and BRD4-NUT fusion oncogene in a 30-year-old female with response to docetaxel and radiotherapy.	Docetaxel	102-111	NUT midline carcinoma family member 1	Homo sapiens	41-44	
16542442-9	2006	CONCLUSION: Docetaxel may be considered for initial chemotherapy in young patients presenting with a midline carcinoma with bone marrow involvement and cytogenetic and molecular genetic finding of a t(15;19)/BRD4-NUT-rearrangement.	Docetaxel	12-21	bromodomain containing 4	Homo sapiens	208-212	
16542442-9	2006	CONCLUSION: Docetaxel may be considered for initial chemotherapy in young patients presenting with a midline carcinoma with bone marrow involvement and cytogenetic and molecular genetic finding of a t(15;19)/BRD4-NUT-rearrangement.	Docetaxel	12-21	NUT midline carcinoma family member 1	Homo sapiens	213-216